Genistein supplement for people with mild cognitive impairment
Tests genistein against a placebo in people with early memory and thinking decline.
Plain-language title generated from the registry record
Registry title: Effectiveness of Genistein in Mild Cognitive Impairment
Key facts
- Where
- Murcia, SpainSee the site
Where in Spain
- UCAM HiTech, Sport & Health Innovation HubMurcia, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidad Católica San Antonio de Murcia
- Trial code
- NCT07385937
- Record updated
- 17 February 2026
- Original description
Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.Read full original descriptionShow less
Effectiveness of Genistein on the Progression of Cognitive Impairment in Patients With Mild Cognitive Impairment: Controlled Clinical Trial
Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.
Inclusion: Patient over 50 years of age; Patient diagnosed with mild cognitive impairment (MCI) for Alzheimer's disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA, 2024) criteria:; MMSE scores between 22 and 30 (inclusive; exceptions may be made for subjects with less than 5 years of education); Evidence of concern about change in cognition, compared to the person's previous level (subjective memory complaint/impairment for more than 6 months in the past year and/or confirmed by the informant and/or physician); A Clinical Dementia Rating (CDR) score of 0.5 with a memory domain score of 0.5; Essentially preserved activities of daily living; Evidence of elevated cortical amyloid by positron emission tomography (PET) with F18-flutemetamol. • Patients will be treated pharmaceutically according to the guidelines.
Exclusion: Diagnosis of a significant neurological disease other than Alzheimer's disease; Moderate depression as assessed by a Geriatric Depression Scale (GDS-D) score >8, or any other serious psychiatric disorder; Having a hormone-dependent neoplastic disease; Diagnosis of significant cerebrovascular disease; Having a serious systemic illness that would prevent completion of the study; Taking supplements containing isoflavones.